CTNM Contineum Therapeutics, Inc.

Nasdaq www.contineum-tx.com


$ 12.18 $ -0.37 (-2.95 %)    

Thursday, 20-Nov-2025 14:41:14 EST
QQQ $ 589.91 $ -21.77 (-3.56 %)
DIA $ 459.89 $ -6.79 (-1.45 %)
SPY $ 656.35 $ -16.56 (-2.46 %)
TLT $ 89.21 $ 0.22 (0.25 %)
GLD $ 375.39 $ 0.21 (0.06 %)
$ 12.43
$ 12.70
$ 12.10 x 1
$ 12.23 x 65
$ 12.11 - $ 12.80
$ 3.35 - $ 16.25
135,060
na
287.12M
$ 0.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-16-2024 03-31-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate o...

 this-lululemon-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 this-biogen-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Core News & Articles

Leerink Partners analyst Faisal Khurshid initiates coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Outperform ratin...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and raises the price ta...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Core News & Articles

Contineum Therapeutics, Inc.

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and lowers the price ta...

Core News & Articles

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and maintains $31 price...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Core News & Articles

Jones Trading analyst Debanjana Chatterjee initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Buy rating and ...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung assumes Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and maintains Pric...

Core News & Articles

Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from ...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate...

Core News & Articles

- Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity- Topline data readout planned for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION